{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:05:09Z","timestamp":1790949909440,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102416","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:28:58Z","timestamp":1713925738000},"page":"102416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-9482","authenticated-orcid":false,"given":"Richard J.","family":"Kelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakazu","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al-Adhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Lallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria F.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102416_bib1","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2019003812","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"137","author":"Brodsky","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102416_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(95)12360-1","article-title":"Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology","volume":"348","author":"Soci\u00e9","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102416_bib4","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2141.1995.tb05371.x","article-title":"Activated platelets in paroxysmal nocturnal haemoglobinuria","volume":"91","author":"Gralnick","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000065658","article-title":"The glycosylphosphatidylinositol anchor and paroxysmal nocturnal haemoglobinuria\/aplasia model","volume":"108","author":"Hall","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib6","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib7","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/jix143","article-title":"Strains responsible for invasive meningococcal disease in patients with terminal complement pathway deficiencies","volume":"215","author":"Rosain","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.rpth.2024.102416_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bjh.15790","article-title":"Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis","volume":"185","author":"Soci\u00e9","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib11","series-title":"Package insert","year":"2023"},{"key":"10.1016\/j.rpth.2024.102416_bib12","article-title":"Summary of product characteristics","year":"2022","journal-title":"Swedish Orphan Biovitrum AB (Sobi)"},{"key":"10.1016\/j.rpth.2024.102416_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102416_bib14","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","article-title":"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial","volume":"9","author":"de Latour","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib15","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","article-title":"Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria","volume":"7","author":"Wong","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102416_bib16","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102416_bib17","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","article-title":"Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria","volume":"101","author":"Wong","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2024.102416_bib18","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2022-163625","article-title":"Long-term safety and efficacy of pegcetacoplan treatment in adults with paroxysmal nocturnal hemoglobinuria","volume":"140","author":"Patriquin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102416_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"143","author":"Kelly","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221091046","article-title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Kulasekararaj","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2024.102416_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1269325","article-title":"Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature","volume":"14","author":"Galli","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2024.102416_bib26","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.rpth.2024.102416_bib27","article-title":"Eculizumab\u2019s unintentional mayhem: a systematic review","volume":"14","author":"Dhanoa","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.rpth.2024.102416_bib28","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/blood-2019-127005","article-title":"Prophylactic antibiotic use and risk of meningococcal infections in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab who received meningococcal vaccination: results from the International PNH Registry","volume":"134","author":"Patriquin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102416_bib29","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/bloodadvances.2023010817","article-title":"Complement and platelets: prothrombotic cell activation requires membrane attack complex-induced release of danger signals","volume":"7","author":"Mannes","year":"2023","journal-title":"Blood Adv"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924001055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T01:32:08Z","timestamp":1722130328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924001055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2475037924001055"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102416","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Apellis Pharmaceuticals, Inc. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102416"}}